1. Finland Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Herantis Pharma Plc

Herantis Pharma Plc

HHEL:HRTIS
1.21
EUR
-0.02
(-1.63%)
48.77MMarket Cap
Mar 04Next Earn
Herantis Pharma Plc
HEL:HRTIS
(Nasdaq Helsinki)

Recent

price

1.21

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
- -
- -
- -
- -
- -
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-1.19
-71.16
-0.64
-3.05
-3.75
-1.02
-0.42
-0.81
-1.3
-1.18
-2.31
-0.64
0.02
-0.24
-0.28
- -
Basic EPS, GAAP
- -
-417.42
-0.88
-1.59
-1.73
-0.7
-0.5
-0.72
-0.97
-1.1
-0.89
-0.61
-0.27
-0.32
-0.26
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.44
-0.61
0.04
5.09
1.4
0.36
0.79
-0.02
0.26
0.74
0.05
- -
0.23
-0.01
-0.07
-0.03
Book Value per Share
-0.55
-372.2
-0.87
0.91
-0.57
-1.32
-0.38
-0.96
-0.28
0.46
0.03
- -
0.23
-0.01
-0.07
-0.03
Tangible Book Value per Share
1
- -
1
3
4
4
5
5
6
8
10
15
17
20
24
25
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
-957,080.22
-826,918.33
-17,476.65
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
2
9
1
1
1
1
1
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
- -
-1
-8
-16
-4
-2
-4
-8
-9
-24
-9
- -
-5
-7
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-1,044,555.44
-820,699.92
-17,493.77
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-1
10
5
2
4
1
5
11
5
4
5
2
2
3
Working Capital
1
2
2
6
8
8
6
6
7
6
4
4
- -
- -
- -
- -
LT Debt
-1
- -
- -
22
6
2
4
- -
2
8
1
- -
5
- -
-2
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
3.34
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
6.51
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-76.52
-115.76
-116.83
-76.41
- -
- -
-193.95
-579.15
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
24
24
27
Market Capitalization
32
49
49

Working Capital

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
5
3
4
Cash, Cash Equivalents & STI
5
3
4
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-953.39%
-1,530.89%
594.73%
Free Cash Flow
6.41%
-1.86%
-6.87%
Net Income, GAAP
-176.14%
-367.38%
34.03%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.24
2025
- -
- -
-0.28
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Herantis Pharma Oyj Herantis Pharma Oyj is a clinical-stage biotechnology company that develops disease-modifying therapies for Parkinson's disease and other neurodegenerative disorders; its lead product candidate, HER-096, is an advanced small synthetic chemical peptidomimetic molecule based on the active site of the cerebral dopamine neurotrophic factor (CDNF) protein, designed for subcutaneous administration to provide neuroprotection by stopping or reversing disease progression. The company focuses on innovative treatments addressing unmet clinical needs in neurology, with HER-096 currently advancing through clinical development following positive topline results from a Phase 1b trial in Parkinson's patients that met all primary and secondary endpoints for safety, tolerability, and pharmacokinetics. Founded in 2008 and headquartered in Espoo, Finland, Herantis Pharma Oyj operates primarily in Europe with global ambitions for its pipeline and employs approximately 11-13 staff. Recent developments include the successful completion of a six-month GLP toxicology study for HER-096 in November 2025, plans to initiate a Phase 2 efficacy trial in early-stage Parkinson's patients during 2026, and ongoing funding secured through EUR 3.6 million in research grants from The Michael J. Fox Foundation and Parkinson's Virtual Biotech for the Phase 1b trial and biomarkers, supplemented by EUR 2.5 million from the European Innovation Council Accelerator's ReTreatPD project and eligibility for up to EUR 15 million equity from the EIC Fund; the company also raised EUR 5.2 million via a directed share issue in February 2025 to support operations through Q2 2026 while pursuing pharmaceutical partnerships.